Close

Alexza Adasuve manufacturing facility wins EU Certificate of GMP Compliance

Related stories

New Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International,...

ST Pharm breaks ground on 2nd oligonucleotide manufacturing plant

ST Pharm said it has taken its first step...

Elevating Biopharmaceutical Projects With The Right CDMO

In the biopharma industry, selecting the right contract development...

Biovian announces over €50 million investment in manufacturing facility in Turku, Finland

Biovian, a leading contract development and manufacturing organization (CDMO)...

New PAT – Based Strategy Stops Membrane Fouling In SP – TFF

A recent article published in the Journal of Membrane...

Alexza Pharmaceuticals, a pharmaceutical company, has received EU Certificate of GMP Compliance for its Adasuve manufacturing facility.

In May 2012, Alexza hosted an EU GMP inspection, which was conducted by the Agencia Espanola de Medicamentos y Productos Sanitarios.

The Spanish authorities, on behalf of the EU, from the inspection of the company’s Mountain View, California facility and additional company responses, considered that the Alexza facility complies with the principles and guidelines of Good Manufacturing Practice set forth in Directive 2003/94/EC.

The initial certificate is valid through 15 May 2015, according to Alexza Pharmaceuticals. Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories